| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 118 | 2022 | 756 | 13.200 |
Why?
|
| Genetic Predisposition to Disease | 77 | 2022 | 786 | 6.580 |
Why?
|
| Polymorphism, Single Nucleotide | 58 | 2021 | 627 | 4.680 |
Why?
|
| Genetic Linkage | 13 | 2011 | 90 | 1.680 |
Why?
|
| Antibodies, Antinuclear | 18 | 2016 | 171 | 1.620 |
Why?
|
| Lupus Nephritis | 15 | 2021 | 193 | 1.590 |
Why?
|
| Autoantibodies | 15 | 2022 | 434 | 1.560 |
Why?
|
| Alleles | 31 | 2020 | 386 | 1.550 |
Why?
|
| NADPH Oxidases | 4 | 2021 | 80 | 1.460 |
Why?
|
| Haplotypes | 28 | 2020 | 174 | 1.450 |
Why?
|
| Genome-Wide Association Study | 14 | 2017 | 240 | 1.400 |
Why?
|
| Genotype | 38 | 2020 | 786 | 1.330 |
Why?
|
| Interleukin-10 | 5 | 2022 | 144 | 1.320 |
Why?
|
| Polymorphism, Genetic | 17 | 2018 | 301 | 1.270 |
Why?
|
| Autoimmune Diseases | 11 | 2017 | 186 | 1.260 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2022 | 24 | 1.190 |
Why?
|
| Autoimmunity | 5 | 2022 | 118 | 1.190 |
Why?
|
| Carrier Proteins | 4 | 2016 | 597 | 1.090 |
Why?
|
| Complement C4 | 4 | 2022 | 15 | 1.090 |
Why?
|
| Genetic Loci | 7 | 2017 | 59 | 1.020 |
Why?
|
| Arthritis, Rheumatoid | 8 | 2020 | 157 | 0.940 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2022 | 124 | 0.930 |
Why?
|
| Humans | 130 | 2022 | 68618 | 0.900 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2022 | 25 | 0.830 |
Why?
|
| Genetic Variation | 8 | 2019 | 220 | 0.820 |
Why?
|
| Up-Regulation | 5 | 2022 | 682 | 0.820 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2013 | 17 | 0.800 |
Why?
|
| E2F Transcription Factors | 1 | 2022 | 48 | 0.790 |
Why?
|
| Gene Expression Regulation | 11 | 2016 | 1293 | 0.730 |
Why?
|
| Case-Control Studies | 25 | 2017 | 1553 | 0.730 |
Why?
|
| MicroRNAs | 5 | 2022 | 447 | 0.720 |
Why?
|
| Promoter Regions, Genetic | 8 | 2015 | 615 | 0.720 |
Why?
|
| Receptors, Complement 3d | 5 | 2015 | 45 | 0.700 |
Why?
|
| B-Lymphocytes | 13 | 2022 | 329 | 0.680 |
Why?
|
| Chromosome Mapping | 13 | 2013 | 188 | 0.670 |
Why?
|
| Female | 78 | 2022 | 38074 | 0.650 |
Why?
|
| Macrophages | 2 | 2021 | 647 | 0.650 |
Why?
|
| Interferon Regulatory Factors | 6 | 2016 | 24 | 0.650 |
Why?
|
| Kidney Diseases | 1 | 2021 | 307 | 0.640 |
Why?
|
| Autophagy-Related Proteins | 2 | 2021 | 17 | 0.590 |
Why?
|
| Chromosomes, Human, Pair 1 | 7 | 2011 | 28 | 0.570 |
Why?
|
| Mice | 36 | 2022 | 8474 | 0.570 |
Why?
|
| Male | 60 | 2022 | 37321 | 0.570 |
Why?
|
| DNA | 13 | 2014 | 597 | 0.560 |
Why?
|
| Membrane Proteins | 5 | 2016 | 617 | 0.560 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2016 | 1 | 0.550 |
Why?
|
| RANK Ligand | 3 | 2016 | 73 | 0.550 |
Why?
|
| Gene Frequency | 10 | 2020 | 207 | 0.540 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 5 | 0.540 |
Why?
|
| Major Histocompatibility Complex | 6 | 2022 | 34 | 0.530 |
Why?
|
| Animals | 45 | 2022 | 20881 | 0.510 |
Why?
|
| Poly(ADP-ribose) Polymerases | 5 | 2003 | 39 | 0.500 |
Why?
|
| Interferon-alpha | 3 | 2016 | 46 | 0.490 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2011 | 4 | 0.480 |
Why?
|
| Chromosomes, Human, X | 3 | 2016 | 24 | 0.480 |
Why?
|
| DNA-Binding Proteins | 9 | 2016 | 700 | 0.470 |
Why?
|
| Immune Tolerance | 6 | 2014 | 114 | 0.460 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 163 | 0.460 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 35 | 0.460 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 14 | 0.460 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2016 | 9 | 0.460 |
Why?
|
| RNA, Messenger | 9 | 2016 | 1664 | 0.460 |
Why?
|
| Osteopontin | 1 | 2013 | 28 | 0.430 |
Why?
|
| Immunoglobulin G | 12 | 2013 | 481 | 0.430 |
Why?
|
| Linkage Disequilibrium | 12 | 2016 | 91 | 0.420 |
Why?
|
| STAT1 Transcription Factor | 3 | 2018 | 35 | 0.420 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2012 | 12 | 0.420 |
Why?
|
| T-Lymphocytes | 10 | 2017 | 597 | 0.410 |
Why?
|
| Genetic Testing | 3 | 2004 | 159 | 0.410 |
Why?
|
| Genome, Human | 4 | 2013 | 62 | 0.390 |
Why?
|
| Risk Factors | 17 | 2018 | 5731 | 0.390 |
Why?
|
| SOXD Transcription Factors | 3 | 2018 | 5 | 0.390 |
Why?
|
| Complement Factor H | 1 | 2011 | 21 | 0.380 |
Why?
|
| Adult | 31 | 2022 | 21403 | 0.380 |
Why?
|
| Introns | 5 | 2015 | 68 | 0.370 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 132 | 0.370 |
Why?
|
| Pravastatin | 1 | 2010 | 4 | 0.360 |
Why?
|
| Apolipoprotein A-I | 1 | 2010 | 29 | 0.360 |
Why?
|
| HLA-DR Antigens | 3 | 2005 | 41 | 0.360 |
Why?
|
| Genes, Immunoglobulin | 5 | 1997 | 56 | 0.350 |
Why?
|
| Molecular Sequence Data | 11 | 2015 | 1447 | 0.320 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2009 | 25 | 0.320 |
Why?
|
| Genomic Imprinting | 1 | 2008 | 10 | 0.320 |
Why?
|
| Peptides | 3 | 2010 | 455 | 0.320 |
Why?
|
| Models, Genetic | 5 | 2018 | 161 | 0.300 |
Why?
|
| Sex Factors | 2 | 2011 | 1266 | 0.300 |
Why?
|
| HLA Antigens | 4 | 2017 | 82 | 0.300 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.290 |
Why?
|
| Arthritis, Experimental | 2 | 2018 | 38 | 0.290 |
Why?
|
| Receptors, IgG | 6 | 2004 | 94 | 0.290 |
Why?
|
| Amino Acid Sequence | 6 | 2019 | 1083 | 0.280 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 30 | 0.280 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 4 | 2013 | 7 | 0.280 |
Why?
|
| Sjogren's Syndrome | 2 | 2017 | 18 | 0.280 |
Why?
|
| Middle Aged | 23 | 2022 | 21147 | 0.280 |
Why?
|
| OX40 Ligand | 3 | 2016 | 7 | 0.280 |
Why?
|
| CD3 Complex | 2 | 2017 | 35 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 2791 | 0.270 |
Why?
|
| Base Sequence | 9 | 2015 | 1015 | 0.260 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 209 | 0.260 |
Why?
|
| Antibodies, Anticardiolipin | 4 | 2013 | 15 | 0.260 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 56 | 0.260 |
Why?
|
| Thyroid Diseases | 1 | 2005 | 33 | 0.250 |
Why?
|
| Antigens, CD | 5 | 2004 | 230 | 0.250 |
Why?
|
| HEK293 Cells | 3 | 2016 | 326 | 0.250 |
Why?
|
| Cohort Studies | 14 | 2018 | 2358 | 0.250 |
Why?
|
| Phenotype | 10 | 2014 | 947 | 0.250 |
Why?
|
| Atherosclerosis | 1 | 2007 | 204 | 0.240 |
Why?
|
| Adolescent | 12 | 2022 | 8912 | 0.240 |
Why?
|
| Transcription, Genetic | 4 | 2015 | 562 | 0.240 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 100 | 0.240 |
Why?
|
| STAT4 Transcription Factor | 4 | 2018 | 12 | 0.240 |
Why?
|
| DNA Methylation | 2 | 2017 | 193 | 0.240 |
Why?
|
| Sensitivity and Specificity | 6 | 2014 | 1753 | 0.230 |
Why?
|
| Rheumatology | 1 | 2004 | 46 | 0.230 |
Why?
|
| Antigen-Antibody Complex | 3 | 2014 | 175 | 0.230 |
Why?
|
| HLA-DRB1 Chains | 4 | 2016 | 21 | 0.230 |
Why?
|
| Immunoglobulin Heavy Chains | 4 | 1997 | 72 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2020 | 2689 | 0.230 |
Why?
|
| Age of Onset | 4 | 2018 | 188 | 0.220 |
Why?
|
| Child | 8 | 2022 | 6405 | 0.220 |
Why?
|
| Ikaros Transcription Factor | 2 | 2014 | 26 | 0.220 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 499 | 0.220 |
Why?
|
| Epistasis, Genetic | 3 | 2012 | 32 | 0.220 |
Why?
|
| Apolipoproteins | 2 | 2014 | 51 | 0.210 |
Why?
|
| Protein Phosphatase 2 | 2 | 2014 | 67 | 0.210 |
Why?
|
| Young Adult | 10 | 2022 | 5717 | 0.210 |
Why?
|
| Acetyltransferases | 1 | 2022 | 49 | 0.210 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 113 | 0.210 |
Why?
|
| Spermine | 1 | 2022 | 49 | 0.210 |
Why?
|
| Gene Expression | 4 | 2020 | 770 | 0.210 |
Why?
|
| Homozygote | 1 | 2022 | 119 | 0.210 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 179 | 0.210 |
Why?
|
| Autophagy | 2 | 2021 | 208 | 0.200 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2016 | 507 | 0.200 |
Why?
|
| Cytokines | 5 | 2014 | 866 | 0.200 |
Why?
|
| Gene Knock-In Techniques | 1 | 2021 | 35 | 0.200 |
Why?
|
| Genetic Association Studies | 7 | 2018 | 103 | 0.190 |
Why?
|
| Immunosuppressive Agents | 3 | 2012 | 514 | 0.190 |
Why?
|
| Monocytes | 1 | 2022 | 210 | 0.190 |
Why?
|
| Mice, Inbred NZB | 9 | 2003 | 37 | 0.190 |
Why?
|
| Protein Binding | 6 | 2015 | 1027 | 0.180 |
Why?
|
| Disease Models, Animal | 8 | 2010 | 2550 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 68 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2012 | 216 | 0.180 |
Why?
|
| Immunoglobulin M | 2 | 2008 | 172 | 0.180 |
Why?
|
| Antigens, Surface | 2 | 2014 | 71 | 0.180 |
Why?
|
| Disease Progression | 3 | 2014 | 1038 | 0.170 |
Why?
|
| Republic of Korea | 2 | 2017 | 23 | 0.170 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2016 | 5 | 0.170 |
Why?
|
| Biomarkers | 5 | 2021 | 1593 | 0.170 |
Why?
|
| Chemokines | 2 | 2010 | 119 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 12 | 2009 | 532 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 24 | 0.170 |
Why?
|
| Immunoglobulin Variable Region | 4 | 1997 | 40 | 0.170 |
Why?
|
| Th17 Cells | 1 | 2020 | 116 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 77 | 0.160 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 2 | 2016 | 7 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2020 | 330 | 0.160 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 7 | 0.160 |
Why?
|
| Synoviocytes | 1 | 2018 | 2 | 0.160 |
Why?
|
| beta Karyopherins | 2 | 2016 | 4 | 0.160 |
Why?
|
| Autoantigens | 4 | 2008 | 91 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 199 | 0.160 |
Why?
|
| Receptors, Fc | 1 | 1998 | 19 | 0.160 |
Why?
|
| Interferon Type I | 2 | 2016 | 32 | 0.150 |
Why?
|
| Pedigree | 2 | 2016 | 159 | 0.150 |
Why?
|
| Nephritis | 3 | 1997 | 37 | 0.150 |
Why?
|
| NF-kappa B | 3 | 2014 | 432 | 0.150 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1851 | 0.150 |
Why?
|
| Alternative Splicing | 3 | 2009 | 93 | 0.150 |
Why?
|
| Genetic Load | 1 | 2017 | 4 | 0.150 |
Why?
|
| Bone Density | 2 | 2010 | 159 | 0.150 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 2 | 2015 | 65 | 0.150 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2017 | 13 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 160 | 0.140 |
Why?
|
| Dinitrobenzenes | 3 | 1987 | 6 | 0.140 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1997 | 8 | 0.140 |
Why?
|
| Histones | 2 | 2014 | 111 | 0.140 |
Why?
|
| Synovial Membrane | 1 | 2016 | 23 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2013 | 1692 | 0.140 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2016 | 2 | 0.140 |
Why?
|
| Artemisinins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2016 | 10 | 0.140 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 3 | 0.140 |
Why?
|
| Forecasting | 3 | 2004 | 277 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 9 | 0.140 |
Why?
|
| HLA-D Antigens | 1 | 2016 | 20 | 0.130 |
Why?
|
| CD11b Antigen | 3 | 2016 | 47 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 19 | 0.130 |
Why?
|
| Osteoarthritis | 1 | 2016 | 73 | 0.130 |
Why?
|
| Indians, North American | 2 | 2012 | 64 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2019 | 880 | 0.130 |
Why?
|
| Aged | 6 | 2022 | 14862 | 0.130 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2015 | 3 | 0.130 |
Why?
|
| CD40 Antigens | 1 | 2015 | 9 | 0.130 |
Why?
|
| Transcription Initiation Site | 1 | 2015 | 11 | 0.130 |
Why?
|
| Logistic Models | 6 | 2017 | 1420 | 0.130 |
Why?
|
| Leptin | 1 | 2015 | 80 | 0.130 |
Why?
|
| Nitrobenzenes | 2 | 1985 | 13 | 0.120 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2014 | 1 | 0.120 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type I | 1 | 2014 | 1 | 0.120 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Interleukin-4 | 1 | 2015 | 69 | 0.120 |
Why?
|
| Ubiquitins | 1 | 2014 | 22 | 0.120 |
Why?
|
| ROC Curve | 4 | 2021 | 392 | 0.120 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 56 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 31 | 0.120 |
Why?
|
| Genetic Markers | 4 | 2012 | 144 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 37 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2012 | 41 | 0.120 |
Why?
|
| Complement C3 | 2 | 2010 | 101 | 0.120 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 3 | 2003 | 11 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2014 | 156 | 0.110 |
Why?
|
| Lymphocyte Activation | 4 | 2001 | 397 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2010 | 32 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2014 | 91 | 0.110 |
Why?
|
| Lipocalins | 1 | 2013 | 7 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 13 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 20 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2013 | 19 | 0.110 |
Why?
|
| Mixed Function Oxygenases | 1 | 2013 | 35 | 0.110 |
Why?
|
| Hemostasis | 1 | 2013 | 32 | 0.110 |
Why?
|
| Indians, South American | 1 | 2012 | 12 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2014 | 183 | 0.110 |
Why?
|
| Gene Dosage | 2 | 2016 | 47 | 0.110 |
Why?
|
| HIV Infections | 1 | 2020 | 791 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 282 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 271 | 0.100 |
Why?
|
| 5' Untranslated Regions | 1 | 2012 | 16 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 2003 | 511 | 0.100 |
Why?
|
| Egg Proteins | 1 | 2012 | 15 | 0.100 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 14 | 0.100 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 22 | 0.100 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 14 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2011 | 22 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2020 | 447 | 0.100 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 49 | 0.100 |
Why?
|
| Reference Values | 2 | 2006 | 579 | 0.100 |
Why?
|
| Family Health | 3 | 2007 | 83 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2008 | 18 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 125 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 4 | 2006 | 492 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 186 | 0.100 |
Why?
|
| Oligopeptides | 2 | 2003 | 152 | 0.100 |
Why?
|
| Interferons | 1 | 2011 | 36 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2016 | 10 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 626 | 0.100 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 8 | 0.100 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 199 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2001 | 32 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 365 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 411 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2011 | 235 | 0.090 |
Why?
|
| fas Receptor | 1 | 2010 | 54 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 290 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 98 | 0.090 |
Why?
|
| Freund's Adjuvant | 1 | 2009 | 7 | 0.090 |
Why?
|
| Principal Component Analysis | 3 | 2016 | 55 | 0.090 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 92 | 0.090 |
Why?
|
| Fibrinolysin | 1 | 2009 | 33 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 142 | 0.090 |
Why?
|
| Photosensitivity Disorders | 1 | 2009 | 7 | 0.090 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2009 | 7 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 202 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 320 | 0.080 |
Why?
|
| Health | 1 | 2009 | 26 | 0.080 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2010 | 125 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2000 | 135 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1988 | 63 | 0.080 |
Why?
|
| Mice, Transgenic | 5 | 1997 | 1033 | 0.080 |
Why?
|
| Antigens, CD19 | 2 | 2012 | 17 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 56 | 0.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2012 | 87 | 0.080 |
Why?
|
| Lipids | 1 | 2010 | 298 | 0.080 |
Why?
|
| Immunoglobulins | 3 | 2010 | 97 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2008 | 112 | 0.080 |
Why?
|
| Antibody Formation | 2 | 1985 | 93 | 0.070 |
Why?
|
| Scleroderma, Systemic | 1 | 2011 | 446 | 0.070 |
Why?
|
| Apolipoprotein B-100 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 529 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 40 | 0.070 |
Why?
|
| Epitopes | 2 | 2006 | 146 | 0.070 |
Why?
|
| Interleukins | 2 | 2020 | 79 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2020 | 201 | 0.070 |
Why?
|
| Phospholipids | 1 | 2007 | 108 | 0.070 |
Why?
|
| China | 1 | 2007 | 138 | 0.070 |
Why?
|
| Rheumatic Diseases | 1 | 2006 | 35 | 0.070 |
Why?
|
| Hybridomas | 3 | 1997 | 25 | 0.070 |
Why?
|
| Proteomics | 1 | 2008 | 246 | 0.070 |
Why?
|
| Genes, MHC Class II | 1 | 2005 | 29 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2020 | 165 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2005 | 17 | 0.070 |
Why?
|
| Codon, Terminator | 1 | 2005 | 6 | 0.070 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 563 | 0.060 |
Why?
|
| RNA | 1 | 2006 | 171 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2007 | 567 | 0.060 |
Why?
|
| Tryptophan | 1 | 2005 | 65 | 0.060 |
Why?
|
| Cell Line | 4 | 2016 | 1752 | 0.060 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2004 | 6 | 0.060 |
Why?
|
| Arginine | 1 | 2005 | 102 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2004 | 15 | 0.060 |
Why?
|
| Rheumatoid Factor | 1 | 2004 | 21 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 17 | 0.060 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 17 | 0.060 |
Why?
|
| Penetrance | 1 | 2004 | 17 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2016 | 954 | 0.060 |
Why?
|
| Genetics, Medical | 1 | 2004 | 17 | 0.060 |
Why?
|
| United States | 5 | 2017 | 7367 | 0.060 |
Why?
|
| Complement System Proteins | 2 | 2003 | 135 | 0.060 |
Why?
|
| Mothers | 1 | 2005 | 172 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2014 | 2007 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 1851 | 0.060 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 38 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2001 | 27 | 0.060 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.060 |
Why?
|
| Calcium | 1 | 1987 | 929 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 144 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2003 | 13 | 0.050 |
Why?
|
| Peptide Library | 1 | 2003 | 16 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2003 | 98 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1174 | 0.050 |
Why?
|
| Apolipoprotein L1 | 2 | 2014 | 16 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2015 | 307 | 0.050 |
Why?
|
| Europe | 2 | 2016 | 196 | 0.050 |
Why?
|
| Korea | 2 | 2002 | 13 | 0.050 |
Why?
|
| Genetic Techniques | 1 | 2002 | 32 | 0.050 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Exons | 2 | 2015 | 122 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 498 | 0.050 |
Why?
|
| Symptom Flare Up | 1 | 2021 | 20 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2015 | 1034 | 0.050 |
Why?
|
| Genes | 1 | 2001 | 86 | 0.050 |
Why?
|
| Proteinuria | 1 | 2021 | 136 | 0.050 |
Why?
|
| Lupus Vulgaris | 1 | 2001 | 5 | 0.050 |
Why?
|
| Autophagosomes | 1 | 2021 | 6 | 0.050 |
Why?
|
| Binding Sites | 3 | 2014 | 631 | 0.050 |
Why?
|
| Immunization | 3 | 2003 | 86 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1745 | 0.050 |
Why?
|
| HIV | 1 | 2020 | 56 | 0.050 |
Why?
|
| Biological Assay | 1 | 2021 | 88 | 0.050 |
Why?
|
| Mice, Inbred DBA | 2 | 2018 | 120 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 127 | 0.040 |
Why?
|
| Lysosomes | 1 | 2021 | 136 | 0.040 |
Why?
|
| Research Design | 1 | 2004 | 729 | 0.040 |
Why?
|
| Complement C1q | 1 | 2000 | 18 | 0.040 |
Why?
|
| Genetics, Population | 2 | 2012 | 21 | 0.040 |
Why?
|
| Prevalence | 2 | 2016 | 1619 | 0.040 |
Why?
|
| Apoptosis | 2 | 2020 | 1641 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 86 | 0.040 |
Why?
|
| Species Specificity | 1 | 2000 | 303 | 0.040 |
Why?
|
| Kidney | 2 | 2013 | 945 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2011 | 238 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 137 | 0.040 |
Why?
|
| Proteins | 2 | 2014 | 474 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2012 | 110 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2673 | 0.040 |
Why?
|
| Crohn Disease | 2 | 2011 | 38 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 24 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 10 | 0.040 |
Why?
|
| Ankle Joint | 1 | 2018 | 57 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2008 | 20 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2012 | 214 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2014 | 753 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2017 | 89 | 0.040 |
Why?
|
| Gene Library | 1 | 1997 | 68 | 0.040 |
Why?
|
| Immunity | 1 | 1997 | 67 | 0.040 |
Why?
|
| Chromatin | 1 | 1997 | 76 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2013 | 228 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1997 | 251 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 6 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 384 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 11 | 0.030 |
Why?
|
| Argentina | 1 | 2016 | 9 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2016 | 13 | 0.030 |
Why?
|
| Chile | 1 | 2016 | 17 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 38 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 19 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 45 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Antimalarials | 1 | 2016 | 71 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 77 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 274 | 0.030 |
Why?
|
| Cell Movement | 1 | 2018 | 630 | 0.030 |
Why?
|
| K562 Cells | 1 | 2015 | 44 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 27 | 0.030 |
Why?
|
| HLA-DR2 Antigen | 1 | 2014 | 4 | 0.030 |
Why?
|
| HLA-DR3 Antigen | 1 | 2014 | 7 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 147 | 0.030 |
Why?
|
| Peptide Fragments | 3 | 2003 | 483 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 35 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 1994 | 26 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 60 | 0.030 |
Why?
|
| Histone Deacetylase 1 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Self Tolerance | 1 | 1994 | 8 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 196 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 54 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 94 | 0.030 |
Why?
|
| Spleen | 1 | 2014 | 301 | 0.030 |
Why?
|
| Clone Cells | 1 | 1994 | 67 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2077 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 20 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 1994 | 261 | 0.030 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 5 | 0.030 |
Why?
|
| California | 2 | 2004 | 99 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 636 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 280 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 1200 | 0.030 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2013 | 4 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 35 | 0.030 |
Why?
|
| Receptors, CXCR5 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 100 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1992 | 85 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 130 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 52 | 0.030 |
Why?
|
| Genetic Pleiotropy | 1 | 2011 | 10 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 32 | 0.020 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2011 | 6 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 53 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2011 | 22 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 208 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 1213 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2011 | 133 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 237 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2010 | 13 | 0.020 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2010 | 95 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1990 | 43 | 0.020 |
Why?
|
| Factor X | 1 | 2009 | 1 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2009 | 10 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 955 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2009 | 118 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 357 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1988 | 16 | 0.020 |
Why?
|
| Antibodies | 1 | 1990 | 241 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 1990 | 155 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 434 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 4655 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 322 | 0.020 |
Why?
|
| Hemocyanins | 1 | 1987 | 14 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 242 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1987 | 155 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 981 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Registries | 1 | 2010 | 733 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2008 | 546 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1030 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1465 | 0.020 |
Why?
|
| Prostaglandins | 1 | 1985 | 65 | 0.020 |
Why?
|
| Solubility | 1 | 1985 | 134 | 0.020 |
Why?
|
| Cross Reactions | 2 | 1995 | 57 | 0.020 |
Why?
|
| Indomethacin | 1 | 1985 | 107 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 1984 | 15 | 0.020 |
Why?
|
| Radiography | 1 | 2006 | 572 | 0.020 |
Why?
|
| COS Cells | 1 | 2004 | 155 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 302 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 16 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 737 | 0.010 |
Why?
|
| Cell Division | 1 | 1985 | 541 | 0.010 |
Why?
|
| Peptide Biosynthesis | 1 | 2003 | 5 | 0.010 |
Why?
|
| snRNP Core Proteins | 1 | 2003 | 5 | 0.010 |
Why?
|
| Multigene Family | 1 | 2003 | 93 | 0.010 |
Why?
|
| Plasma Cells | 1 | 2003 | 19 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 1 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 710 | 0.010 |
Why?
|
| Japan | 1 | 2002 | 68 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 166 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2001 | 16 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 489 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 765 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 376 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 215 | 0.010 |
Why?
|
| Germany | 1 | 2000 | 67 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1999 | 32 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1998 | 50 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 3187 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 66 | 0.010 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 1997 | 4 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1997 | 134 | 0.010 |
Why?
|
| Colitis | 1 | 1997 | 156 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1995 | 22 | 0.010 |
Why?
|
| Algorithms | 1 | 2001 | 1196 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1994 | 73 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1994 | 181 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1994 | 358 | 0.010 |
Why?
|
| Swine | 1 | 1995 | 672 | 0.010 |
Why?
|
| Genes, Synthetic | 1 | 1993 | 5 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1993 | 60 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1993 | 30 | 0.010 |
Why?
|
| Glomerulonephritis | 1 | 1993 | 77 | 0.010 |
Why?
|
| Aging | 1 | 1998 | 911 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 1173 | 0.000 |
Why?
|